{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:03Z","timestamp":1791105723303,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.1006\/exnr.1998.6996","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:46:56Z","timestamp":1032191216000},"page":"204-220","source":"Crossref","is-referenced-by-count":140,"title":["Effect of Repeatedl-DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat"],"prefix":"10.1006","volume":"155","author":[{"given":"Brian","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/exnr.1998.6996_RF1","first-page":"106","article-title":"Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man","volume":"15","author":"Aellig","year":"1977","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"key":"10.1006\/exnr.1998.6996_RF2","first-page":"67","article-title":"Dopamine receptor stimulating agonists in the treatment of Parkinson's disease","volume":"30","author":"Agid","year":"1979","journal-title":"Biomedicine"},{"key":"10.1006\/exnr.1998.6996_RF3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-1-4684-7618-7_28","article-title":"Reduction of dopamine receptor activity differentially alters striatal neuropeptide mRNA levels","volume":"221","author":"Angulo","year":"1987","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1006\/exnr.1998.6996_RF4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(86)90290-6","article-title":"Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA","volume":"130","author":"Angulo","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF5","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1093\/nar\/12.23.9179","article-title":"The complete sequence of a full length cDNA for human liver glyeraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species","volume":"12","author":"Arcari","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1006\/exnr.1998.6996_RF6","first-page":"791","article-title":"l","volume":"101","author":"Barbeau","year":"1969","journal-title":"Can. Med. Assoc. J."},{"key":"10.1006\/exnr.1998.6996_RF7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys: Correlation with [3","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0304-3940(83)90548-7","article-title":"Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity","volume":"25","author":"Bevan","year":"1983","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.1998.6996_RF9","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa","volume":"94","author":"Bordet","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6996_RF10","first-page":"231","article-title":"Ropinirole in the symptomatic treatment of Parkinson's disease","volume":"45","author":"Brooks","year":"1995","journal-title":"J. Neural Trans. Suppl."},{"key":"10.1006\/exnr.1998.6996_RF11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(78)90856-5","article-title":"Long-term treatment of parkinsonism with bromocriptine","volume":"8","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1006\/exnr.1998.6996_RF12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in Parkinsonism","volume":"4","author":"Calne","year":"1974","journal-title":"BMJ"},{"key":"10.1006\/exnr.1998.6996_RF13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1460-9568.1994.tb00328.x","article-title":"Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum","volume":"6","author":"Campbell","year":"1994","journal-title":"Eur. J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0024-3205(91)90526-H","article-title":"Naloxone reversesl","volume":"48","author":"Carey","year":"1991","journal-title":"Life Sci."},{"key":"10.1006\/exnr.1998.6996_RF15","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0169-328X(93)90132-9","article-title":"Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat","volume":"19","author":"Chritin","year":"1993","journal-title":"Brain Res. Mol. Brain. Res."},{"key":"10.1006\/exnr.1998.6996_RF17","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1073\/pnas.82.12.4291","article-title":"Sequence and expression of the rat prodynorphin gene","volume":"82","author":"Civelli","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6996_RF18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00168809","article-title":"Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"338","author":"Clarke","year":"1988","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF19","doi-asserted-by":"crossref","first-page":"9631","DOI":"10.1073\/pnas.91.20.9631","article-title":"6-hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons","volume":"91","author":"Cole","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6996_RF20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1006\/exnr.1998.6996_RF21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","article-title":"l","volume":"7","author":"Cooper","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6996_RF22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism: Chronic treatment withl","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/exnr.1998.6996_RF23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM197603112941101","article-title":"Treatment of Parkinson's disease with aporphines: Possible role of growth hormone","volume":"294","author":"Cotzias","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/exnr.1998.6996_RF24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.870050203","article-title":"A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induce dyskinesias in Parkinson's disease: Implications for future strategies in treatment","volume":"5","author":"Crossman","year":"1990","journal-title":"Mov. Dis."},{"key":"10.1006\/exnr.1998.6996_RF25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.2042-7158.1977.tb11450.x","article-title":"The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents","volume":"29","author":"Dolphin","year":"1977","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/exnr.1997.6431","article-title":"Enhancement of the behavioural response to apomorphine following repeated treatment in the 6-hydroxydiopamine-lesioned rat is temporally correlated with a rise in pre-proenkephalin-B, but not pre-proenkephalin-A, gene expression","volume":"144","author":"Duty","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/exnr.1997.6771","article-title":"Topographical organisation of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat","volume":"150","author":"Duty","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0006-8993(91)90667-K","article-title":"Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output neurons of 6-hydroxydopamine lesioned rats","volume":"552","author":"Engber","year":"1991","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF29","first-page":"417","article-title":"Expression and pharmacological characterization of the human D3 dopamine receptor","volume":"268","author":"Freedman","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1006\/exnr.1998.6996_RF30","first-page":"275","article-title":"Dose- and duration-dependent tolerance to rotational effects of apomorphine in a rat model of Parkinsonism","volume":"272","author":"Gancher","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1006\/exnr.1998.6996_RF31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1006\/exnr.1998.6996_RF32","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1523\/JNEUROSCI.11-04-01016.1991","article-title":"Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridisation histochemical analysis","volume":"11","author":"Gerfen","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0014-4886(92)90125-A","article-title":"Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys","volume":"117","author":"Gomez-Mancilla","year":"1992","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs onl","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharm."},{"key":"10.1006\/exnr.1998.6996_RF35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0006-8993(90)90439-I","article-title":"Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat","volume":"514","author":"Graham","year":"1990","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1460-9568.1996.tb01578.x","article-title":"Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum","volume":"8","author":"Hajji","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0006-8993(79)91066-7","article-title":"Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii","volume":"171","author":"Hammond","year":"1979","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioural responses tol","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00002512-199609030-00001","article-title":"Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease","volume":"9","author":"Henry","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1006\/exnr.1998.6996_RF40","series-title":"The Basal Ganglia","article-title":"Modulation of glutamate transmission in the basal ganglia by enadoline, a selective kappa-opioid receptor agonist, in the marmoset and rat","author":"Hill","year":"1996"},{"key":"10.1006\/exnr.1998.6996_RF41","unstructured":"Hille, C. J. M. P. Maneuf, J. M. Brotchie, Activation of delta opioid receptors inhibits GABAergic function in the globus pallidus of the rat, Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0404.1985.tb03173.x","article-title":"Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease","volume":"71","author":"Hoehn","year":"1985","journal-title":"Acta Neurol. Scand."},{"key":"10.1006\/exnr.1998.6996_RF43","first-page":"223","article-title":"Effects of long-term administration of antipsychotic drugs on enkephalinergic neurons","volume":"24","author":"Hong","year":"1980","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1006\/exnr.1998.6996_RF44","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1073\/pnas.81.23.7651","article-title":"Molecular cloning and sequence determination of rat preproenkephalin cDNA: Sensitive probe for studying transcriptional changes in rat tissues","volume":"81","author":"Howells","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6996_RF45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson's disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6996_RF46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/exnr.1996.6380","article-title":"Problems with current pharmacological treatment of Parkinson's disease","volume":"144","author":"Hurtig","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mds.870100512","article-title":"Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease","volume":"10","author":"Inzelberg","year":"1995","journal-title":"Mov. Dis."},{"key":"10.1006\/exnr.1998.6996_RF48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1523\/JNEUROSCI.05-06-01513.1985","article-title":"Differential visualisation of dopamine and noradrenaline uptake sites in rat brain using3","volume":"5","author":"Javitch","year":"1985","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0169-328X(92)90108-N","article-title":"Reserpine treatment stimulates enkephalin and D2 dopamine receptor gene expression in the rat striatum","volume":"15","author":"Jaber","year":"1992","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0169-328X(95)00064-Y","article-title":"Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: An in situ hybridization study","volume":"32","author":"Jaber","year":"1995","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0169-328X(94)90206-2","article-title":"Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary","volume":"23","author":"Jaber","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-8993(90)90522-D","article-title":"Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes","volume":"507","author":"Jiang","year":"1990","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(76)90728-5","article-title":"Bromocriptine and levodopa (with or without carbidopa) in parkinsonism","volume":"7","author":"Kartzinel","year":"1976","journal-title":"Lancet"},{"key":"10.1006\/exnr.1998.6996_RF54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0024-3205(96)00021-5","article-title":"Levodopa but not bromocriptine induces AP-1 and CREB DNA-binding activity in the dopamine-depleted striatum of the rat","volume":"58","author":"Kashihara","year":"1996","journal-title":"Life Sci."},{"key":"10.1006\/exnr.1998.6996_RF55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-3940(91)90774-N","article-title":"Evidence for a projection from the globus pallidus to the entopeduncular nucleus in the rat","volume":"128","author":"Kincaid","year":"1991","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.1998.6996_RF56","first-page":"S23","article-title":"Treating motor fluctuations with controlled-release levodopa preparations","volume":"44","author":"Koller","year":"1994","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF57","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1523\/JNEUROSCI.14-09-05623.1994","article-title":"Amphetamine regulates gene expression in rat striatum via transcription factor CREB","volume":"14","author":"Konradi","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF58","first-page":"263","article-title":"Lisuride and transdihydrolisuride: differences in action on central dopaminergic functions in dependence on the location and state of receptors","volume":"37","author":"Krejci","year":"1985","journal-title":"Pol. J. Pharmacol. Pharm."},{"key":"10.1006\/exnr.1998.6996_RF59","first-page":"131","article-title":"Lisuride treatment in Parkinson's disease: Clinical and pharmacokinetic studies","volume":"37","author":"Le Witt","year":"1983","journal-title":"Adv. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF60","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.33.8.1009","article-title":"Comparison of pergolide and bromocriptine therapy in parkinsonism","volume":"33","author":"Le Witt","year":"1983","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF61","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","article-title":"Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease","volume":"44","author":"Lees","year":"1981","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1006\/exnr.1998.6996_RF62","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","article-title":"Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report","volume":"307","author":"Lees","year":"1993","journal-title":"BMJ"},{"key":"10.1006\/exnr.1998.6996_RF63","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1212\/WNL.43.12.2587","article-title":"Cabergoline in Parkinson's disease: Long-term follow-up","volume":"43","author":"Lera","year":"1993","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(86)91502-7","article-title":"Regulation of the concentration of dynorphin A1\u201318","volume":"398","author":"Li","year":"1986","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF65","first-page":"403","article-title":"Regulation of the metabolism of striatal dynorphin by the dopaminergic system","volume":"246","author":"Li","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1006\/exnr.1998.6996_RF66","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM197612162952504","article-title":"Treatment of Parkinson's disease with bromocriptine","volume":"295","author":"Lieberman","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/exnr.1998.6996_RF67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/WNL.29.3.363","article-title":"Bromocriptine in Parkinson's disease: Further studies","volume":"29","author":"Lieberman","year":"1979","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0006-8993(95)00358-W","article-title":"Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease","volume":"683","author":"Maneuf","year":"1995","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/exnr.1994.1007","article-title":"On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus","volume":"125","author":"Maneuf","year":"1994","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF70","first-page":"31","article-title":"Distribution and excretion in the rat and monkey of [82","volume":"211","author":"Markey","year":"1979","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1006\/exnr.1998.6996_RF71","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/brain\/50.3-4.637","article-title":"Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys)","volume":"50","author":"Martin","year":"1927","journal-title":"Brain"},{"key":"10.1006\/exnr.1998.6996_RF72","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/brain\/115.3.809","article-title":"A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia","volume":"115","author":"Mitchell","year":"1992","journal-title":"Brain"},{"key":"10.1006\/exnr.1998.6996_RF73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mds.870070106","article-title":"Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey","volume":"7","author":"Mitchell","year":"1992","journal-title":"Mov. Dis."},{"key":"10.1006\/exnr.1998.6996_RF74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0006-8993(85)90102-7","article-title":"Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography","volume":"339","author":"Mitchell","year":"1985","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF75","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/brain\/112.6.1533","article-title":"The role of the subthalamic nucleus in experimental chorea: Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies","volume":"112","author":"Mitchell","year":"1989","journal-title":"Brain"},{"key":"10.1006\/exnr.1998.6996_RF76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","article-title":"Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison withl","volume":"49","author":"Morissette","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF77","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00001756-199702100-00018","article-title":"A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease","volume":"8","author":"Newman","year":"1997","journal-title":"Neuroreport"},{"key":"10.1006\/exnr.1998.6996_RF78","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1006\/exnr.1998.6996_RF80","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/jnnp.39.11.1101","article-title":"Bromocriptine in Parkinsonism: Long-term treatment dose response, and comparison with levodopa","volume":"39","author":"Parkes","year":"1976","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1006\/exnr.1998.6996_RF81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410090109","article-title":"Lisuride in parkinsonism","volume":"9","author":"Parkes","year":"1981","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00003495-198121050-00002","article-title":"Adverse effects of antiparkinsonian drugs","volume":"21","author":"Parkes","year":"1981","journal-title":"Drugs"},{"key":"10.1006\/exnr.1998.6996_RF83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003495-197917050-00006","article-title":"Bromocriptine in the treatment of parkinsonism","volume":"17","author":"Parkes","year":"1979","journal-title":"Drugs"},{"key":"10.1006\/exnr.1998.6996_RF84","series-title":"The Rat Brain in Stereotatic Coordinates","author":"Paxinos","year":"1996"},{"key":"10.1006\/exnr.1998.6996_RF85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.410420508","article-title":"Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias","volume":"42","author":"Piccini","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/brain\/121.3.527","article-title":"Cortical motor overactivation in parkinsonian patients withl","volume":"121","author":"Rascol","year":"1998","journal-title":"Brain"},{"key":"10.1006\/exnr.1998.6996_RF87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.37.5.826","article-title":"Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up","volume":"37","author":"Rinne","year":"1987","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF88","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.39.3.336","article-title":"Lisuride, a dopamine agonist in the treatment of early Parkinson's disease","volume":"39","author":"Rinne","year":"1989","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0006-8993(90)90952-8","article-title":"Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: Electrophysiological data","volume":"518","author":"Robledo","year":"1990","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/286157a0","article-title":"The role of D-1 and D-2 receptors","volume":"286","author":"Schachter","year":"1980","journal-title":"Nature"},{"key":"10.1006\/exnr.1998.6996_RF91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000117449","article-title":"Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high-doses of pergolide and cessation of levodopa","volume":"37","author":"Schwarz","year":"1997","journal-title":"Eur. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0306-4522(96)00022-X","article-title":"The subthalamic nucleus and the external pallidum: Two tightly interconnected structures that control the output of the basal ganglia in the monkey","volume":"73","author":"Shink","year":"1996","journal-title":"Neuroscience"},{"key":"10.1006\/exnr.1998.6996_RF93","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00002826-199704000-00001","article-title":"Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuation and dyskinesias","volume":"20","author":"Stocchi","year":"1997","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6996_RF94","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1073\/pnas.80.12.3841","article-title":"Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks","volume":"80","author":"Tang","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6996_RF95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0006-2952(92)90040-P","article-title":"Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation","volume":"44","author":"Thomas","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(85)90673-9","article-title":"The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum","volume":"118","author":"Traub","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF97","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1523\/JNEUROSCI.08-12-04755.1988","article-title":"Differential expression of preproenkephalin and preprodynorphin mRNA in striatal neurons: High levels of preproenkephalin expression depend on cerebral cortical afferents","volume":"8","author":"Uhl","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6996_RF98","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6996_RF99","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0006-8993(87)91149-8","article-title":"Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions","volume":"412","author":"Voorn","year":"1987","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6996_RF100","first-page":"966","article-title":"Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors","volume":"50","author":"Watts","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1006\/exnr.1998.6996_RF101","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cne.900900304","article-title":"Studies on the subthalamus of rhesus monkey. II Hyperkinesia and other physiological effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys","volume":"90","author":"Whittier","year":"1949","journal-title":"J. Comp. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF102","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"280","author":"Yahr","year":"1969","journal-title":"Arch. Neurol."},{"key":"10.1006\/exnr.1998.6996_RF103","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1073\/pnas.83.24.9827","article-title":"Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain","volume":"83","author":"Young","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488698969965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488698969965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:42:31Z","timestamp":1576507351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488698969965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["S0014488698969965"],"URL":"https:\/\/doi.org\/10.1006\/exnr.1998.6996","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}